Furthermore, dipyridamole (an FDA-approved drug known to potentiate adenosine signaling) phenocopies adenosine A2A receptor agonism in terms of suppressing both NETosis and venous thrombosis. This evidence concerns the gene ADORA2A and Venous thrombosis.